Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
In the Diabetes Prevention Program, treatment of subjects with impaired glucose tolerance with metformin >3.2 years reduced the risk of developing type 2 diabetes by 30% compared with placebo. This study describes the mechanisms of this effect. In proportional hazards regression models with 2,155 subjects, changes in weight, the insulinogenic index (IGR), fasting insulin, and proinsulin were predictive of diabetes, though to different degrees within each group. The mean change in weight, fasting insulin, and proinsulin, but not IGR, differed between groups during the study. The 1.7-kg weight loss with metformin versus a 0.3-kg gain with placebo alone explained 64% of the beneficial metformin effect on diabetes risk. Adjustment for weight, fasting insulin, proinsulin, and other metabolic factors combined explained 81% of the beneficial metformin effect, but it remained nominally significant (P = 0.034). After the addition of changes in fasting glucose, 99% of the group effect was explained and is no longer significant. Treatment of high-risk subjects with metformin results in modest weight loss and favorable changes in insulin sensitivity and proinsulin, which contribute to a reduction in the risk of diabetes apart from the associated reductions in fasting glucose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In Japan, a lifestyle intervention for diabetes prevention was effective in persons with impaired fasting glucose only if they had an additional risk factor such as elevated HbA1c or impaired glucose tolerance.21”
From Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredIn the citing paper
“Weight loss was a strong predictor of diabetes prevention in both the metformin and placebo groups with weight loss accounting for 64% of the metformin versus placebo effect on diabetes prevention (7).”
From Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study (2012) · cites this paper as [7]
In the citing paper
“Metformin lowers glucose and reduces risk for diabetes in part through weight loss (2,7,16,17).”
From Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study (2012) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 2×
“Fasting insulin, however, has been shown to be strongly related to insulin resistance (7).”
BackgroundMethodSelf-citationEffect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Self-citationPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Research works printed but not linked: 1
- Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA, Iowa State University Press,1980
Cited by
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., Kushner, F. G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.001 · Cited by 1,324
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051bab · Cited by 343
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
“Weight loss accounted for 64 % of the beneficial effect of metformin versus placebo on diabetes risk [90].”
BackgroundThe prevention of type 2 diabetes
F. T. D. P. P. R. G., Crandall, J. P., Knowler, W. C., Kahn, S. E., Marrero, D., Florez, J. C., Bray, G. A., Haffner, S. M., Hoskin, M., & Nathan, D. M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0843 · Cited by 261
Self-citationWu, R.-R., Zhao, J.-P., Guo, X.-F., He, Y.-Q., Fang, M.-S., Guo, W.-B., Chen, J.-D., & Li, L.-H. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010079 · Cited by 230
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s003 · Cited by 204
Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05245-x · Cited by 192
Self-citationfor the Diabetes Prevention Program Research Group, Aroda, V. R., Knowler, W. C., Crandall, J. P., Perreault, L., Edelstein, S. L., Jeffries, S. L., Molitch, M. E., Pi-Sunyer, X., Darwin, C., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4361-9 · Cited by 194
“While no single covariate completely explained the beneficial effect of metformin vs placebo, the combination of weight, fasting insulin and proinsulin levels, and other metabolic factors explained 81% of the beneficial outcomes with metformin [17].”
BackgroundInfluentialSelf-citationKnowler (2011) · doi:10.1001/archinternmed.2011.367 · Cited by 194
Self-citationKnowler, W. C. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_16-1 · Cited by 194
Self-citationPathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia
Siddiqui, J. A., Pothuraju, R., Khan, P., Sharma, G., Muniyan, S., Seshacharyulu, P., Jain, M., Nasser, M. W., & Batra, S. K. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.11.002 · Cited by 178
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s003 · Cited by 144
Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program
Mather, K. J., Funahashi, T., Matsuzawa, Y., Edelstein, S., Bray, G. A., Kahn, S. E., Crandall, J., Marcovina, S., Goldstein, B., Goldberg, R., et al. (2008) · Diabetes · doi:10.2337/db07-1419 · Cited by 161
“Change in weight was a clear contributor to the diabetes prevention effect in this group and in other analyses has been found to account for as much as 64% of the total effect of metformin (33).”
BackgroundSelf-citationAmerican Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s003 · Cited by 132
Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1605 · Cited by 156
Self-citationGreenland, P., Alpert, J. S., Beller, G., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., Kushner, F. G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.002 · Cited by 176
Gillett, M., Royle, P., Snaith, A., Scotland, G., Poobalan, A., Imamura, M., Black, C., Boroujerdi, M., Jick, S., Wyness, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16330 · Cited by 146
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s003 · Cited by 144
Ladson, G., Dodson, W. C., Sweet, S. D., Archibong, A. E., Kunselman, A. R., Demers, L. M., Williams, N. I., Coney, P., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.12.002 · Cited by 138
“Given the absence of glycemic improvement, weight loss may be the primary metabolic benefit of metformin in the present study (31).”
Benefits of Modest Weight Loss on the Management of Type 2 Diabetes Mellitus
Lau, D. C. W., & Teoh, H. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.03.023 · Cited by 108
Survey of diabetes knowledge and practices of dental hygienists.
Boyd, L. D., & Hartman-Cunningham, M. L. (2008) · PubMed · Cited by 92
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 94
“conversion of impaired glucose tolerance to clinical diabetes).(101) Recent meta‐analyses have demonstrated clinically significant weight loss with metformin in nondiabetic populations with conditions associated with weight gain, ie, women with gestational diabetes,(102) women with polycystic ovary syndrome,(103) and…”
BackgroundMetformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study
Wang, M., Tong, J.-H., Zhu, G., Liang, G.-M., Yan, H., & Wang, X. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.021 · Cited by 82
Goldberg, R., Temprosa, M., Otvos, J., Brunzell, J., Marcovina, S., Mather, K., Arakaki, R., Watson, K., Horton, E., & Barrett-Connor, E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1452 · Cited by 74
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin
O’Brien, M. J., Perez, A., Scanlan, A. B., Alos, V. A., Whitaker, R. C., Foster, G. D., Ackermann, R. T., Ciolino, J. D., & Homko, C. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.01.008 · Cited by 77
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Self-citationHemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012151.pub2 · Cited by 60
Metformin and Type 2 Diabetes Prevention
Aroda, V. R., & Ratner, R. E. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0020 · Cited by 70
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Review: Metformin: Potential benefits and use in chronic kidney disease
PILMORE, H. L. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01328.x · Cited by 69
Lipodystrophy: A paradigm for understanding the consequences of "overloading" adipose tissue
Lim, K., Haider, A., Adams, C., Sleigh, A., & Savage, D. B. (2020) · Physiological Reviews · doi:10.1152/physrev.00032.2020 · Cited by 110
Targeting the Consequences of the Metabolic Syndrome in the Diabetes Prevention Program
Goldberg, R. B., & Mather, K. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241893 · Cited by 67
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 104
Does Menopause Increase Diabetes Risk? Strategies for Diabetes Prevention in Midlife Women
Kim, C. (2012) · Women s Health · doi:10.2217/whe.11.95 · Cited by 68
“Metformin reduces weight and is also thought to reduce hepatic gluconeogenesis and improve hepatic sensitivity [93].”
BackgroundDefining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus
STOLAR, M. W. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0471 · Cited by 65
Andújar-Plata, P., Pi-Sunyer, X., & Laferrère, B. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.022 · Cited by 59
“[20] Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, et al.”
BackgroundEarly Response to Preventive Strategies in the Diabetes Prevention Program
Maruthur, N. M., Ma, Y., Delahanty, L. M., Nelson, J. A. E., Aroda, V. R., White, N. H., Marrero, D. G., Brancati, F. L., & Clark, J. M. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2548-4 · Cited by 63
Goldberg, R. B., Temprosa, M. G., Mather, K. J., Orchard, T. J., Kitabchi, A. E., Watson, K. E., & for the Diabetes Prevention Program Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2471 · Cited by 54
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 59
“There have been concerns raised about increased risk of infections associated with use of DPP4 inhibitors due to its immune modulating effects.”
BackgroundInfluentialThe GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance
Klein, A. B., Nicolaisen, T. S., Johann, K., Fritzen, A. M., Mathiesen, C. V., Gil, C., Pilmark, N. S., Karstoft, K., Blond, M. B., Quist, J. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111258 · Cited by 57
Nollet, E. E., Westenbrink, B. D., de Boer, R. A., Kuster, D. W. D., & van der Velden, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018641 · Cited by 45
Impact of weight changes on the incidence of diabetes mellitus: a Korean nationwide cohort study
Kim, E. S., Jeong, J. S., Han, K., Kim, M. K., Lee, S., Park, Y., Baek, K. H., Moon, S. D., Han, J.-H., Song, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21550-3 · Cited by 44
Knowler, W. C., Doherty, L., Edelstein, S. L., Bennett, P. H., Dabelea, D., Hoskin, M., Kahn, S. E., Kalyani, R. R., Kim, C., Pi-Sunyer, F. X., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00022-1 · Cited by 39
Self-citationSheu, W. H., Rosman, A., Mithal, A., Chung, N., Lim, Y. T., Deerochanawong, C., Soewondo, P., Lee, M., Yoon, K., & Schnell, O. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.04.019 · Cited by 42
Lexis, C. P. H., van der Horst‐Schrivers, A. N. A., Lipšic, E., Valente, M. A. E., Kobold, A. C. M., de Boer, R. A., van Veldhuisen, D. J., van der Harst, P., & van der Horst, I. C. C. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000090 · Cited by 36
Florez, H. J., Temprosa, M. G., Orchard, T. J., Mather, K. J., Marcovina, S. M., Barrett-Connor, E. L., Horton, E., Saudek, C. D., Pi-Sunyer, X. F., Ratner, R. E., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12220 · Cited by 36
The effect of comprehensive lifestyle intervention or metformin on obesity in young women☆
Lim, S., Norman, R., Clifton, P., & Noakes, M. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.10.006 · Cited by 31
Prediabetes: To treat or not to treat?
Moutzouri, E., Tsimihodimos, V., Rizos, E. C., & Elisaf, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.007 · Cited by 36
Growth differentiation factor 15 (GDF-15) in kidney diseases
Delrue, C., Speeckaert, R., Delanghe, J., & Speeckaert, M. M. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.02.003 · Cited by 35
Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0014 · Cited by 29
Self-citationPratte, K., Johnson, A., Beals, J., Bullock, A. K., Manson, S. M., Jiang, L., & Program, A. T. S. D. P. F. I. D. P. (2019) · Diabetes Care · doi:10.2337/dc18-1964 · Cited by 28
Altered islet prohormone processing: a cause or consequence of diabetes?
Ramzy, A., & Kieffer, T. J. (2021) · Physiological Reviews · doi:10.1152/physrev.00008.2021 · Cited by 32
Horsdal, H. T., Johnsen, S. P., Søndergaard, F. L., & Rungby, J. (2008) · Diabetologia · doi:10.1007/s00125-008-0947-6 · Cited by 24
“However, it has recently been reported that high proinsulin levels (which are reduced by metformin [24]) are pro-atherosclerotic in women, but not in men [25], and this might provide at least some explanation for our finding.”
Perez, A., Alos, V. A., Scanlan, A. B., Maia, C. M., Davey, A., Whitaker, R. C., Foster, G. D., Ackermann, R. T., & O’Brien, M. J. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.10.011 · Cited by 25
“Metformin has also been found to inducemodestweight loss among individuals with prediabetes, which is considered the primary mechanism explaining its efficacy in preventing or delaying the onset of type 2 diabetes [21].”
Sciannimanico, S. M., Grimaldi, F., Vescini, F., Pergola, G. D., Iacoviello, M., Licchelli, B., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190507125847 · Cited by 22
The gastrointestinal tract is a major source of the acute metformin-stimulated rise in GDF15
Kincaid, J. W. R., Rimmington, D., Tadross, J. A., Cimino, I., Zvetkova, I., Kaser, A., Richards, P., Patel, S., O’Rahilly, S., & Coll, A. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-51866-2 · Cited by 21
McDiarmid, S., Harvie, M., Johnson, R., Vyas, A., Aglan, A., Moran, J., Ruane, H., Hulme, A., Sellers, K., & Issa, B. G. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14592 · Cited by 22
Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes
Zhu, Y. X., Fang, Y., Medina, D., Bartke, A., & Yuan, R. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111597 · Cited by 20
Characterizing the genetic architecture of drug response using gene-context interaction methods
Sadowski, M., Thompson, M., Mefford, J., Haldar, T., Oni‐Orisan, A., Border, R., Pazokitoroudi, A., Cai, N., Ayroles, J. F., Sankararaman, S., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100722 · Cited by 21
Insulin resistance in bipolar disorder: relevance to routine clinical care
Calkin, C., & Alda, M. (2015) · Bipolar Disorders · doi:10.1111/bdi.12330 · Cited by 17
“The Diabetes Prevention Program Outcomes Study (a double-blind, randomized, controlled study of the efficacy of metformin versus placebo in preventing or delaying the onset of T2D in people with elevated fasting glucose or impaired glucose tolerance) determined that metformin was safe for long-term use and was well to…”
MethodWei, M., Wang, L., Liu, X., Deng, Y., Yang, S., Pan, W., Zhang, X., Xu, G., Xiao, S., & Deng, C. (2024) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000011363 · Cited by 18
“39,40 In the current study, metformin slightly reduced body weight in lymphedema models but had no significant effect on hindlimb circumference and tail volume.”
Rodent diet aids and the fallacy of caloric restriction
Wolf, A. M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111584 · Cited by 16
“The weight loss effects of metformin are well known (Lachin et al., 2007), and metformin is an effective weight-loss drug also in non-diabetic humans (Knowler et al.”
BackgroundThe Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity
Cusi, K. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-260-1_1 · Cited by 19
Therapeutic potential of metformin in normal glucose tolerant persons with metabolic syndrome
Kamenova, P. (2020) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2019.1711184 · Cited by 14
Steps Toward the Meaningful Translation of Prevention Strategies for Type 2 Diabetes
Cefalu, W. T. (2012) · Diabetes Care · doi:10.2337/dc12-0119 · Cited by 14
Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome
Riemann, A., Blaschke, M., Jauho-Ghadimi, A., Siggelkow, H., & Gollisch, K. S. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154294 · Cited by 14
Bruce, K., Garrido, A. N., Zhang, S., & Lam, T. K. T. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2025 · Cited by 14
Htet, T. D., Godneva, A., Liu, Z., Chalmers, E., Kolobkov, D. S., SNAITH, J. R., Richens, R., Toth, K., Danta, M., Hng, T., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037859 · Cited by 13
Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes
Knowler, W. C., & Crandall, J. P. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1268-5 · Cited by 14
Self-citationLi, J., Zheng, R., Shen, Y., Zhuo, Y., Lu, L., Song, J., Li, J., Lai, M., Zhu, H., Hu, M., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156294 · Cited by 13
Metformin and GDF15: where are we now?
Kincaid, J. W. R., & Coll, A. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00764-6 · Cited by 11
Risk of Type 2 Diabetes Among Individuals with Excess Weight: Weight Trajectory Effects
Owora, A. H., Allison, D. B., Zhang, X., Gletsu-Miller, N. A., & Gadde, K. M. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01486-9 · Cited by 11
Metformin Protects Cardiovascular Health in People With Diabetes
Chen, C., Yuan, S., Zhao, X., Qiao, M., Li, S., He, N., Huang, L., & Lyu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.949113 · Cited by 9
Metformin and its redox-related mechanisms of action in type 2 diabetes
Vezza, T., Luna-Marco, C., Rovira‐Llopis, S., & Víctor, V. M. (2023) · Redox Experimental Medicine · doi:10.1530/rem-23-0015 · Cited by 8
Garbuzova, E. V., Shcherbakova, L. V., Rymar, O. D., Khudiakova, A. D., Шрамко, В. С., & Ragino, Y. I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091403 · Cited by 8
Deciphering metformin action in obese mice: A critical re-evaluation of established protocols
Kaplanian, M., Philippe, C., Eid, S. A., Hackl, M. T., Metz, M., Beghini, M., Luca, A. C., Kautzky‐Willer, A., Scherer, T., & Fürnsinn, C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154956 · Cited by 9
Cohen, P. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.024 · Cited by 8
Yew, M. J., Heywood, S., Ng, J., West, O. M., Pal, M., Kueh, A., Lancaster, G., Myers, S., Yang, C., Liu, Y.-Y., et al. (2024) · Diabetes, obesity and metabolism · doi:10.1111/dom.15484 · Cited by 6
“10 In addition, Met may assist in the prevention and management of T2D via its weight-lowering effects, 11 a finding proposed to involve the mitochondrial stress response protein, growth differentiation factor 15.”
BackgroundArreola, E. V., Knowler, W. C., & Hanson, R. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac509 · Cited by 7
Self-citationSmith, S. C., Taylor, A. J., Weintraub, W. S., Kushner, F. G., Lauer, M. S., Benjamin, J. M., Budoff, M. J., Fayad, Z. A., Foster, E., Greenland, P., et al. (2011) · Cited by 7
Robert, A., Chester, A. L., Morton-McSwain, C., Ayubi, S. U. A., Bhat, K., Brimson, P., Buch, S. C., Cannon, Y., Groark, S., Hanks, S., et al. (2011) · InTech eBooks · doi:10.5772/23872 · Cited by 4
“(Figure 10) The prototypic model of the ‘Diabetes Prevention Program’ that did reduce new onset of diabetes (Orchard et al., 2005; Lachin et al., 2007; DPP Research Group, 2006; DPP, 2000) and influence other components of the metabolic syndrome in high risk subjects (Knowler et al, 2002) has proved hard to replicate…”
BackgroundBailey, C. J. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1331-8_8 · Cited by 4
Taylor, J., Weintraub, W. S., WENGER, N. K., Kushner, F. G., Lauer, M. S., Shaw, L. J., Smith, S. C., Fayad, Z. A., Foster, E., Hlatky, M. A., et al. (2011) · Cited by 3
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
“Of note, weight loss was a primary contributor to T2DM prevention, with additional weight loss conferring a greater degree of protection [12,13].”
BackgroundMetformin increases glycolysis and the stress-induced cytokine GDF15 but not FGF21 in humans
Kolnes, K. J., Møller, P. M., Kruse, R., Christensen, M. H., Kjøbsted, R., Hey-Mogensen, M., Andersen, B., Handberg, A., & Højlund, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1797525 · Cited by 2
“Nevertheless, metformin has been shown to reduce the risk of type 2 diabetes in individuals at high risk (2), an effect that has mainly been ascribed to a modest metformin-induced weight loss in individuals with prediabetes (2, 4).”
Bianchi, C., Prato, S. D., Rothberg, A. E., & Nauck, M. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70674 · Cited by 3
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes
Bourassa, M. G., & Berry, C. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0016-0 · Cited by 2
“In the DPP [41], treatment of patients with IGT with metformin over 3.2 years decreased the risk of developing type 2 DM by 30% [ 41 ].”
MethodInfluentialThe caloric restriction fallacy, rodent diet aids and the tumor suppression theory of agingPreprint
Wolf, A. M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/a2689 · Cited by 2
Liu, K., Chen, S., Cao, M., Xu, X., Jiang, L., Liu, Z., Lai, J., Pan, X., Zhang, Y., Xu, L., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152496 · Cited by 1
Interventional Trials to Prevent Diabetes: Diabetes Prevention Program
Aroda, V. R., & Ratner, R. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3314-9_9 · Cited by 2
The effects of metformin plus sulfonylurea therapy on clinical features of the metabolic syndrome
Koprivica, B., Živković, T. B., & Ille, T. (2010) · Medicinski pregled · doi:10.2298/mpns1010611k · Cited by 1
“Prema najnovijim preporukama Američke dijabetološke asocijacije i Evropskog udruženja za dijabetes, pored bazalnog insulina, SU su lekovi izbora kod neuspeha monoterapije metforminom u lečenju dijabetesa tipa 2, zbog niske cene i dobre efikasnosti [30].”
BackgroundJacobs, A. K., Smith, S. C., Taylor, A. J., Weintraub, W. S., Kushner, F. G., Lauer, M. S., Benjamin, J. M., Budoff, M. J., Fayad, Z. A., Foster, E., et al. (2011) · Cited by 1
Taylor, A. J., Weintraub, W. S., WENGER, N. K., Kushner, F. G., Lauer, M. S., & Shaw, L. J. (2010) · Cited by 1
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T. B., Januzzi, J. L., Johnson, M. R., et al. (2013) · Cited by 1
Metformin and/or Exercise Training Affect Metabolic Health in Men and Women with Prediabetes
Malin, S. K. (2011) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · doi:10.7275/2175194
Preventing Diabetes: Lessons Learned from the Diabetes Prevention Program and Its Follow-Up
Bray, G. A. (2009) · Obesity and Weight Management · doi:10.1089/obe.2009.0603
Effects of zoledronic acid combined with metformin on bones of DB/DB micePreprint
Yang, X., Zhao, W., Ma, W., Yin, X., & Lin, Y. (2020) · doi:10.21203/rs.3.rs-103504/v1
Metadata
- Authors
- Lachin, J. M., Christophi, C. A., Edelstein, S. L., Ehrmann, D. A., Hamman, R. F., Kahn, S. E., Knowler, W. C., Nathan, D. M., & on behalf of the DPP Research Group
- Affiliations
- George Washington University (US)
- University of Chicago (US)
- University of Colorado Anschutz (US)
- University of Washington (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-04-01
- Volume
- 56
- Issue
- 4
- Pages
- 1153-1159
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2533728
- OpenAlex
- W2167320654
- Cited by
- 107
- References
- 29
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 9 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 1 · 2013: 6 · 2012: 7
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Diabetes Association
- National Institutes of Health
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK048489)
- National Institute of Child Health and Human Development
- National Center for Research Resources
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes prevention, impaired glucose tolerance, weight loss, fasting insulin, proinsulin, insulinogenic index, insulin sensitivity, fasting blood glucose, Diabetes Prevention Program
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Life Style, Metformin, Placebos, Multivariate Analysis, Proportional Hazards Models, Body Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.